Tenaya Therapeutics (TNYA) CFO files first Form 3 ownership report

Rhea-AI Filing Summary

Tenaya Therapeutics, Inc. lists Chief Financial Officer Eric J Hyllengren as a reporting person in an initial Form 3 insider ownership report. The structured data show no buy or sell transactions, no derivative positions, and a neutral net buy/sell status at the time of filing.

Key Figures

Buy shares reported: 0 shares Sell shares reported: 0 shares Derivative transactions: 0 +1 more

4 metrics

Buy shares reported 0 shares buyShares in transaction summary for this Form 3

Sell shares reported 0 shares sellShares in transaction summary for this Form 3

Derivative transactions 0 derivativeTransactionCount in transaction summary

Net buy/sell shares 0 shares netBuySellShares in transaction summary with neutral direction

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Understanding Insider Trading Forms →

Available on EDGAR 07/14/2026 - 09:04 PM Accepted by SEC EDGAR 07/14/2026 - 09:03 PM Learn about SEC filing dates

FAQ

Who is the reporting person in Tenaya Therapeutics (TNYA) latest Form 3 filing?

The reporting person is Eric J Hyllengren, who serves as Chief Financial Officer of Tenaya Therapeutics, Inc. This Form 3 identifies him as an insider subject to SEC beneficial ownership reporting rules.

What role does Eric J Hyllengren hold at Tenaya Therapeutics (TNYA)?

Eric J Hyllengren is listed as the company’s Chief Financial Officer. In this capacity, he is an officer and reporting person, triggering the requirement to file an initial Form 3 statement of beneficial ownership with the SEC.

Does the Tenaya Therapeutics (TNYA) Form 3 show any insider share purchases or sales?

No. The transaction summary shows 0 buyShares and 0 sellShares, with buyCount and sellCount both at zero. This indicates no reportable open-market purchases or sales are included in this Form 3 data.

Are any derivative securities reported in this Tenaya Therapeutics (TNYA) Form 3?

No derivative securities are listed. The derivative summary is empty and the transaction summary shows 0 derivativeTransactionCount and 0 exerciseShares, indicating no options or similar instruments are reported here.

What is the overall trading direction indicated in Tenaya Therapeutics (TNYA) Form 3?

The filing’s transaction summary shows a netBuySellDirection of "neutral" and netBuySellShares of 0. Combined with zero buys and sells, this reflects no trading activity reported in this initial ownership statement.

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0104
Estimated average burden
hours per response:			0.5

1. Name and Address of Reporting Person^*

Hyllengren Eric J

(Last) (First) (Middle)

C/0 TENAYA THERALEUTICS, INC.

171 OYSTER POINT BLVD., 5TH FLOOR

(Street)

SOUTH SAN FRANCISCO CALIFORNIA 94080

(City) (State) (Zip)

UNITED STATES

(Country)

2. Date of Event Requiring Statement (Month/Day/Year)
07/13/2026

3. Issuer Name and Ticker or Trading Symbol
Tenaya Therapeutics, Inc. [ TNYA ]

3a. Foreign Trading Symbol

5. If Amendment, Date of Original Filed (Month/Day/Year)

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Financial Officer

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

No securities are beneficially owned.

	/s/ Jennifer Drimmer Rokovich, Attorney-in-Fact	07/14/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 3: SEC 1473 (03-26)